Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001709401-22-000014
Filing Date
2022-08-09
Accepted
2022-08-09 08:17:52
Documents
54
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ruby-20220630.htm   iXBRL 10-Q 1524959
2 EX-31.1 exhibit311certification.htm EX-31.1 19946
3 EX-31.2 exhibit312certification.htm EX-31.2 19858
4 EX-32.1 exhibit321certification.htm EX-32.1 6665
5 EX-32.2 exhibit322certification.htm EX-32.2 6654
  Complete submission text file 0001709401-22-000014.txt   5027719

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ruby-20220630.xsd EX-101.SCH 28068
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ruby-20220630_cal.xml EX-101.CAL 46228
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ruby-20220630_def.xml EX-101.DEF 110548
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ruby-20220630_lab.xml EX-101.LAB 397773
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ruby-20220630_pre.xml EX-101.PRE 237841
48 EXTRACTED XBRL INSTANCE DOCUMENT ruby-20220630_htm.xml XML 607124
Mailing Address 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139
Business Address 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139 617-679-9600
Rubius Therapeutics, Inc. (Filer) CIK: 0001709401 (see all company filings)

EIN.: 042688109 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38586 | Film No.: 221146518
SIC: 2836 Biological Products, (No Diagnostic Substances)